Business Description
PCI Biotech Holding ASA
NAICS : 325412
SIC : 2834
ISIN : NO0010405640
Compare
Compare
Traded in other countries / regions
PCIB.Norway4QG.Germany0JGL.UKPCIBO.Sweden IPO Date
2008-06-25Description
PCI Biotech Holding ASA is a biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The PCI technology works by inducing light-triggered endosomal release. PCI is applied to three distinct anticancer paradigms; fimaCHEM which is an enhancement of chemotherapeutics for localized treatment of cancer, fimaVACC which is T-cell induction technology for therapeutic vaccination, and fimaNAc which is nucleic acid therapeutics delivery. Its therapeutic product candidate is the photosensitizer fimaporfin (Amphinex) which can unlock the intracellular capsules where active compounds are trapped.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 79.68 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 25.4 | |||||
| 3-Year EPS without NRI Growth Rate | 14.6 | |||||
| 3-Year FCF Growth Rate | 18.7 | |||||
| 3-Year Book Growth Rate | -39.2 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 20.29 | |||||
| 9-Day RSI | 31.07 | |||||
| 14-Day RSI | 36.44 | |||||
| 6-1 Month Momentum % | 3.02 | |||||
| 12-1 Month Momentum % | -5.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.69 | |||||
| Quick Ratio | 9.69 | |||||
| Cash Ratio | 8.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.1 | |||||
| Shareholder Yield % | 1.58 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -49.19 | |||||
| ROA % | -42.7 | |||||
| ROIC % | -406.16 | |||||
| ROC (Joel Greenblatt) % | -2073.87 | |||||
| ROCE % | -50.83 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.29 | |||||
| Price-to-Tangible-Book | 1.12 | |||||
| EV-to-EBIT | -0.61 | |||||
| EV-to-EBITDA | -0.63 | |||||
| EV-to-FCF | -0.51 | |||||
| Price-to-Net-Current-Asset-Value | 1.25 | |||||
| Price-to-Net-Cash | 1.4 | |||||
| Earnings Yield (Greenblatt) % | -161.4 | |||||
| FCF Yield % | -50.97 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PCI Biotech Holding ASA Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.072 | ||
| Beta | 1.43 | ||
| Volatility % | 95.38 | ||
| 14-Day RSI | 36.44 | ||
| 14-Day ATR (€) | 0.004285 | ||
| 20-Day SMA (€) | 0.12735 | ||
| 12-1 Month Momentum % | -5.54 | ||
| 52-Week Range (€) | 0.0907 - 0.228 | ||
| Shares Outstanding (Mil) | 37.33 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PCI Biotech Holding ASA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PCI Biotech Holding ASA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
PCI Biotech Holding ASA Frequently Asked Questions
What is PCI Biotech Holding ASA(FRA:4QG)'s stock price today?
The current price of FRA:4QG is €0.11. The 52 week high of FRA:4QG is €0.23 and 52 week low is €0.09.
When is next earnings date of PCI Biotech Holding ASA(FRA:4QG)?
The next earnings date of PCI Biotech Holding ASA(FRA:4QG) is 2024-08-28.
Does PCI Biotech Holding ASA(FRA:4QG) pay dividends? If so, how much?
PCI Biotech Holding ASA(FRA:4QG) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers